Patents by Inventor Abdol-Hossein Rezaeian

Abdol-Hossein Rezaeian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of Lysyl Oxidases
    Publication number: 20240075015
    Abstract: Described herein are compounds that block the activity of LOX family members having good IC50 values, no cellular toxicity below 10 ?M, induce sensitization of the cells to doxorubicin, strong activity in a recombinant LOX/LOXL2 activity, and a chemical structure that is drug-like and does not have a PAINS flag, as well as, methods of treatment using the compounds with respect to cancer, organ fibrosis, neurodegenerative and cardiovascular diseases.
    Type: Application
    Filed: June 12, 2023
    Publication date: March 7, 2024
    Inventors: Ozgur Sahin, Campbell McInnes, Ozge Saatci, Chad Beneker, Abdol-Hossein Rezaeian, Metin Cetin
  • Inhibitors of lysyl oxidases
    Patent number: 11712437
    Abstract: Described herein are novel compounds that block the activity of LOX family members having good IC50 values, no cellular toxicity below 10 ?M, induce sensitization of the cells to doxorubicin, strong activity in a recombinant LOX/LOXL2 activity, and a chemical structure that is drug-like and does not have a PAINS flag, as well as, methods of treatment using the compounds with respect to cancer, organ fibrosis, neurodegenerative and cardiovascular diseases.
    Type: Grant
    Filed: March 13, 2022
    Date of Patent: August 1, 2023
    Assignee: University of South Carolina
    Inventors: Ozgur Sahin, Campbell McInnes, Ozge Saatci, Chad Beneker, Abdol-Hossein Rezaeian, Metin Cetin
  • NOVEL INHIBITORS OF LYSYL OXIDASES
    Publication number: 20220378753
    Abstract: Described herein are novel compounds that block the activity of LOX family members having good IC50 values, no cellular toxicity below 10 ?M, induce sensitization of the cells to doxorubicin, strong activity in a recombinant LOX/LOXL2 activity, and a chemical structure that is drug-like and does not have a PAINS flag, as well as, methods of treatment using the compounds with respect to cancer, organ fibrosis, neurodegenerative and cardiovascular diseases.
    Type: Application
    Filed: March 13, 2022
    Publication date: December 1, 2022
    Applicant: University of South Carolina
    Inventors: Ozgur Sahin, Campbell Mclnnes, Ozge Saatci, Chad Beneker, Abdol-Hossein Rezaeian, Metin Cetin